GlaxoSmithKline Poaches AstraZeneca PLC Exec to Replace Exiting Pharma Head

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-glaxosmithkline.jpg" NAME"GlaxoSmithKline Poaches AstraZeneca PLC Exec to Replace Exiting Pharma Head" ALT"GlaxoSmithKline Poaches AstraZeneca PLC Exec to Replace Exiting Pharma Head"January 19, 2017By Mark Terry, BioSpace... Source: BioSpace

Continue ReadingGlaxoSmithKline Poaches AstraZeneca PLC Exec to Replace Exiting Pharma Head

<b>Martin Shkreli's</b> Complaint Leads to a $100 Million FTC Settlement for This Biotech

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-mallinckrot.jpg" NAME"Martin Shkreli's Complaint Leads to a $100 Million FTC Settlement for This Biotech" ALT"Martin Shkreli's Complaint Leads to a $100 Million FTC Settlement for This Biotech"January 19, 2017By…

Continue Reading<b>Martin Shkreli's</b> Complaint Leads to a $100 Million FTC Settlement for This Biotech

Not So Different After All: 5 Overlapping Skills Needed in Life Science Academia vs. Industry

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-overlapping-skills-academia-vs-industry.jpg" NAME"Not So Different After All: 5 Overlapping Skills Needed in Life Science Academia vs. Industry" ALT"Not So Different After All: 5 Overlapping Skills Needed in Life Science Academia…

Continue ReadingNot So Different After All: 5 Overlapping Skills Needed in Life Science Academia vs. Industry

AbbVie's $175 Million Gamble Pays Off as Ablynx RA Drug Meets Goal in Phase II Study

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-breaking-news-clinical.jpg" NAME"AbbVie's $175 Million Gamble Pays Off as Ablynx RA Drug Meets Goal in Phase II Study" ALT"AbbVie's $175 Million Gamble Pays Off as Ablynx RA Drug Meets Goal…

Continue ReadingAbbVie's $175 Million Gamble Pays Off as Ablynx RA Drug Meets Goal in Phase II Study